Skip to content
Jenburkt Pharmaceuticals logo

Jenburkt Pharmaceuticals

JENBURPH NSE
₹880.00 up 4.05 (0.46%)
Market Cap
₹388 Cr
P/E
11.83

Jenburkt Pharmaceuticals (JENBURPH) share price was ₹875.95 at the 28 Oct 2026 close; market capitalisation ₹387 Cr; P/E (TTM) 11.78; sector Healthcare. The share price fell 17.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 0.1% year on year to ₹35.51 Cr and net profit fell 24.4% year on year to ₹5.89 Cr (compared with Jun 2025). Promoters held 46.62% of Jenburkt Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 61/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹875.95 −275.75 −23.94% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹388 Cr
P/E (TTM)
11.83
EBITDA
₹54.00 Cr
Return on Equity
17.63%
Debt to Equity
0.01
Book Value
₹446.47
EPS (TTM)
₹74.39
52W High
₹1,321.00
52W Low
₹845.00

Price-based figures as of 29 Oct 2026, 10:35 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,768.0035.074,24,202 Cr5.080.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,657.5087.652,56,376 Cr15.300.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,609.5072.361,75,331 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.70108.091,18,204 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.6026.291,17,865 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,339.0034.681,11,764 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.5032.711,10,313 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Jenburkt Pharmaceuticals (this company)
₹880.0011.83388 Cr1.972.36%17.63%23.16%178 Cr33 Cr
Median 8 companies₹1,566.7534.881,18,035 Cr4.720.72%14.56%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

61 Good
Overall score

Data confidence 100/100

Category scores

Quality Strong 69
Returns, margins, earnings quality 22% weight
Valuation Strong 73
Cheap vs sector & own history 24% weight
Growth Average 50
Sales & profit trajectory 9% weight
Financial Health Strong 90
Solvency, leverage, coverage 9% weight
Momentum Poor 27
Trend strength, vol-adjusted 12% weight
Ownership Average 48
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.7%

Weaknesses

1
  • The company has delivered a poor sales growth of 9.08% over past five years.

Technical Indicators

Oscillators

Bullish

Bearish
2
Neutral
4
Bullish
3

Overall

Bearish

Bearish
12
Neutral
4
Bullish
3

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
13.01% higher than 3Y

change over 1 year

Net Income Growth
8.1% lower than 3Y

change over 1 year

Cash Flow Change
-4.98%

change over 1 year

EBITDA Margin Change
1.48%

change over 1 year Operating margin 16.98% · Jun 2026

Analyst Forecasts

Forecast For
Mar 27 consensus · Price
₹1,370 +49.8% vs Sep 26
Reported High Mean Low

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
29.18
38.29
35.66
38.84
32.54
41.22
36.89
41.05
35.53
45.56
43.02
44.63
35.51
Expenses
22.22
29.19
28.47
28.99
23.26
29.79
28.07
30.19
26.58
32.45
35.59
30.38
29.48
Operating Profit
6.96
9.1
7.19
9.85
9.28
11.43
8.82
10.86
8.95
13.11
7.43
14.25
6.03
OPM %
23.85%
23.77%
20.16%
25.36%
28.52%
27.73%
23.91%
26.46%
25.19%
28.78%
17.27%
31.93%
16.98%
Other Income
1.04
1.1
1.35
1.19
1.41
1.85
1.58
1.88
2.06
2.08
1.82
0.4
1.51
Interest
0.07
0.07
0.07
0.06
0.11
0.12
0.11
0.11
0.11
0.11
0.12
0.13
0.13
Depreciation
0.5
0.59
0.63
0.62
0.52
0.64
0.78
0.79
0.72
0.74
0.83
0.81
0.64
PBT
7.43
9.54
7.84
10.36
10.06
12.52
9.51
11.84
10.18
14.34
8.3
13.71
6.77
Tax %
27.73%
23.27%
31.12%
23.94%
26.34%
23.32%
31.65%
27.87%
23.48%
29.08%
28.55%
20.86%
13%
Net Profit
5.37
7.32
5.4
7.88
7.42
9.6
6.51
8.54
7.79
10.16
5.93
10.85
5.89
EPS (₹)
12.17
16.59
12.24
17.86
16.81
21.75
14.75
19.35
17.65
23.02
13.44
24.58
13.35
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
85
94
103
115
123
119
109
124
137
142
152
169
169
Expenses
70
77
84
91
98
99
89
97
106
109
111
125
128
Operating Profit
15
16
20
24
25
20
20
27
30
33
40
44
41
OPM %
18%
18%
19%
21%
20%
17%
18%
22%
22%
23%
27%
26%
24%
Other Income
2
3
3
3
3
4
4
5
5
5
7
6
6
Interest
0
0
0
0
0
1
0
0
0
0
0
0
0
Depreciation
3
2
2
2
1
2
2
2
2
2
3
3
3
PBT
14
17
20
25
27
21
22
30
33
35
44
47
43
Tax %
33%
36%
34%
32%
26%
30%
24%
25%
25%
26%
27%
25%
—
Net Profit
10
11
14
17
20
15
16
22
25
26
32
35
33
EPS (₹)
20.76
23.19
29.06
37.5
43.14
32.4
35.95
48.59
55.76
58.87
72.64
78.72
74.39
Div. Payout %
30%
31%
28%
24%
24%
25%
28%
25%
26%
26%
25%
26%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
4
4
4
4
Reserves
29
36
50
57
73
75
94
113
118
141
167
193
Borrowings
7
5
6
0
7
3
5
7
3
0
4
2
Other Liabilities
21
12
16
16
18
21
17
18
16
19
19
26
Total Liabilities
61
58
76
77
103
104
120
143
141
164
195
225
Fixed Assets
12
12
11
10
10
12
11
11
10
10
15
19
CWIP
0
0
0
0
1
0
0
0
1
1
40
46
Investments
0
1
2
5
5
4
7
8
11
17
21
27
Other Assets
49
45
64
62
87
88
103
123
119
136
120
132
Total Assets
61
58
76
77
103
104
120
143
141
164
195
225
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
9
8
10
16
13
15
19
9
17
8
28
27
Investing
1
0
-10
1
-11
-3
-19
-1
3
-1
-17
-19
Financing
1
-5
1
-18
-2
-11
-1
-6
-21
-7
-8
-9
Net Cash Flow
11
2
1
-1
0
1
0
3
-1
0
3
-2
Free Cash Flow
8
5
10
16
11
11
18
7
15
6
8
13
CFO/OP
88
82
85
103
80
104
127
62
83
49
102
88
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
32
23
32
40
68
55
47
45
45
50
50
53
Inventory Days
107
109
128
73
99
120
92
115
92
103
109
154
Days Payable
54
44
72
44
66
58
56
83
67
75
100
91
Cash Conversion Cycle
85
88
89
69
101
117
83
77
70
78
59
115
Working Capital Days
-11
6
10
25
35
32
17
16
31
36
31
41
ROCE %
42%
40%
39%
42%
37%
26%
24%
26%
27%
26%
27%
27%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jenburkt Pharmaceuticals insights

65 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs0.03%Promot.46.62%Others18.96%Public34.39%As ofSep 2026

Documents

Frequently Asked Questions about Jenburkt Pharmaceuticals

What does Jenburkt Pharmaceuticals Ltd do?
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]
Where is Jenburkt Pharmaceuticals Ltd (JENBURPH) listed?
Jenburkt Pharmaceuticals Ltd trades as JENBURPH on the NSE and under code 524731 on the BSE.
Which sector does Jenburkt Pharmaceuticals Ltd belong to?
Jenburkt Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd has a market capitalisation of ₹388.37 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd trades at a PE ratio of 11.83 as of 29 Oct 2026, on earnings per share of ₹74.39, against a book value of ₹446.47 per share.
What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd?
Over the last 52 weeks Jenburkt Pharmaceuticals Ltd has traded between ₹845 and ₹1,321 as of 29 Oct 2026.
Does Jenburkt Pharmaceuticals Ltd pay dividends?
Jenburkt Pharmaceuticals Ltd has a dividend yield of 2.36%.
What is the Return on Equity (ROE) of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd reported a return on equity of 17.63%. Its debt-to-equity ratio is 0.01.

Company Information

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

Website jenburkt.com
Listed 2026-08-17
Face Value ₹ 10
Shares Outstanding 44,13,300

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524731.md for Jenburkt Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month